Home › Polycythemia Vera › New York › New York City
Polycythemia Vera clinical trials in New York City, NY
5 studies for Polycythemia Vera are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
- NYP/Weill Cornell Medical Center, New York
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
- Mount Sinai School of Medicine, New York
- Weill Cornell Medicine, New York
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center, New York
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
RecruitingPhase 2
- Ruttenberg Treatment Center, New York
Polycythemia Vera trials in other cities
- Durham, NC5 studies
- Irvine, CA3 studies
- Coral Springs, FL3 studies
- Miami, FL3 studies
- Los Angeles, CA3 studies
- Houston, TX3 studies
- Nashville, TN3 studies
- Tampa, FL3 studies
- Columbus, OH3 studies
- Salt Lake City, UT3 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.